Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 in Metastatic Castration-Resistant Prostate Cancer
NCT01385293Phase 2Terminated
- Start
- Aug 2011
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buparlisib in metastatic castration-resistant prostate cancer (mCRPC). Started Aug 2011; status: terminated.
02
Drugs
buparlisib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01385293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01385293.